Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

What Happened: A notable Form 4 filing on Monday with the U.S. Securities and Exchange Commission revealed that Meury, Chief Executive Officer at Incyte, exercised stock options for 0 shares of INCY, ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

So, we marked another World Sickle Cell Day on Thursday, June 19. But truthfully, what was there to celebrate? I can’t speak ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

The ASX biotech sector's best EOFY performer has come from left field: the local and European focused medicinal cannabis ...

Mesoblast (NASDAQ:MESO – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based ...